1'-Hydroxy bufuralol-d₉

| Cat. No.: | HY-122277S | | |
|--------------------|---------------------------|-------|----------|
| CAS No.: | 1185069-74-2 | | |
| Molecular Formula: | $C_{16}H_{14}D_{9}NO_{3}$ | | |
| Molecular Weight: | 286.41 | | |
| Target: | Isotope-Labeled Compounds | | |
| Pathway: | Others | | |
| Storage: | Powder | -20°C | 3 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |

| | | • |
|----------|-----|-----|
| 3 years | DĎĎ | Pr |
| 6 months | | ote |
| 1 month | | ins |

| BIOLOGICAL ACTIVITY | | | |
|---------------------|---|--|--|
| | | | |
| Description | 1'-Hydroxy bufuralol-d ₉ is a deuterium labeled 1'-Hydroxy bufuralol (HY-122277). 1'-Hydroxy bufuralol, the main metabolite of bufuralol, can reflect CYP2D activity ^{[1][2]} . | | |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | |

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.

[2]. Evangelos P Daskalopoulos, et al. D₂-dopaminergic receptor-linked pathways: critical regulators of CYP3A, CYP2C, and CYP2D. Mol Pharmacol. 2012 Oct;82(4):668-78.

[3]. H Yamazaki, et al. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol. 1994 Sep;46(3):568-77.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA



Product Data Sheet

OH

D |_D

NH

OH